Form 4: Humacyte Director Kathleen Sebelius Reports Stock Transactions

Kathleen Sebelius, a director at Humacyte, Inc., reported the acquisition and disposal of common stock and stock options on September 10, 2024.

Summary

• On September 10, 2024, Kathleen Sebelius, a director of Humacyte, Inc., engaged in multiple transactions involving the company's stock.
• She acquired 4,521 shares of common stock through the exercise of stock options at a price of $4.34 per share.
• She also acquired 2,479 shares of common stock through the exercise of stock options at a price of $3.35 per share.
• Additionally, she sold 3,634 shares of common stock at a weighted average price of $5.41 and 1,548 shares at a weighted average price of $5.39.
• Following these transactions, Sebelius directly owns 41,207 shares of Humacyte common stock and holds options to purchase 6,021 more shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to the market regarding their investment activities in the company.

Stakeholder Impact

• The transactions may provide insights to stakeholders regarding the director's view on the company's stock value.

Key Dates